4D Molecular Therapeutics FDMT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | -$209.18M-6.6% | -$196.14M-11.2% | -$176.44M-9.7% | ||
| $4.91M+4.6% | $4.69M+2.6% | $4.57M+1.6% | $4.5M-0.6% | $4.53M-2.6% | ||
| $19.48M-11.5% | $22.02M-8.4% | $24.04M-7.6% | $26.01M-4.1% | $27.13M+3.9% | ||
| —— | —— | —— | $5.27M+7,963% | -$67K-108% | ||
| $6.34M-22.2% | $8.15M— | —— | —— | —— | ||
| —— | —— | —— | $7.07M+12.7% | $6.27M+75.3% | ||
| $1.19M+667% | -$209K— | —— | —— | —— | ||
| $3.01M+2.8% | $2.93M+2.7% | $2.86M+8.7% | $2.63M+12.5% | $2.33M+13.7% | ||
| -$3.32M-3.9% | -$3.19M-24.2% | -$2.57M-18.8% | -$2.16M-13.7% | -$1.9M-15.3% | ||
| —— | —— | -$183.5M-10.3% | -$166.39M-8.6% | -$153.26M-13.9% | ||
| —— | —— | —— | $3.42M-7.6% | $3.71M-2.1% | ||
| -$56.03M+39.7% | -$92.97M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $124.44M+10.2% | $112.96M+7,054% | $1.58M-22.3% | $2.03M-89.0% | $18.42M-94.5% | ||
| —— | —— | -$138.98M-24.2% | -$111.9M+21.2% | -$142.07M-42.4% | ||
| $4.6M-2.8% | $4.73M-12.9% | $5.44M-16.6% | $6.52M-15.2% | $7.69M+7.1% | ||
| —— | —— | —— | —— | -$47K-215% | ||
| -$3.32M-3.9% | -$3.19M-24.2% | -$2.57M-18.8% | -$2.16M-13.7% | -$1.9M-15.3% | ||
| —— | —— | —— | —— | —— | ||
| $3.01M+2.8% | $2.93M+2.7% | $2.86M+8.7% | $2.63M+12.5% | $2.33M+13.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $7.5M+33.3% | $5.63M+50.0% | $3.75M+100% | $1.88M— | ||
| —— | $984K-47.7% | $1.88M-32.3% | $2.78M-24.4% | $3.68M-19.6% | ||
| —— | —— | —— | —— | —— | ||
| $1.19M+667% | -$209K— | —— | —— | —— | ||
| -$3.32M-3.9% | -$3.19M-24.2% | -$2.57M-18.8% | -$2.16M-13.7% | -$1.9M-15.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | $307K+33.3% | $230.25K+50.0% | $153.5K+100% | $76.75K— | ||
| —— | —— | -$185.05M-9.0% | -$169.81M-8.2% | -$156.96M-13.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does 4D Molecular Therapeutics generate?
- 4D Molecular Therapeutics (FDMT) generated -$205.8M in operating cash flow over the trailing twelve months.
- What is 4D Molecular Therapeutics's free cash flow?
- After $1.6M of capital expenditures, 4D Molecular Therapeutics's free cash flow was -$206.4M over the trailing twelve months, down 49.1% year over year.
- Where does 4D Molecular Therapeutics's cash flow data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
